These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16697451)

  • 1. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms.
    Bidus MA; Webb JC; Seidman JD; Rose GS; Boice CR; Elkas JC
    Gynecol Oncol; 2006 Jul; 102(1):5-7. PubMed ID: 16697451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
    Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
    J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
    Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
    J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
    Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
    Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
    Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
    J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
    Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.
    Oliverio G; Canuti D; Tononi A; Scarpellini M; Panzini I; Galli I; Ravaioli A
    J Chemother; 1999 Aug; 11(4):301-5. PubMed ID: 10465133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
    Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
    Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
    Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
    Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives].
    Bliumenberg AG; Gorbacheva LB; Gorbunova VA; Kozachenko VP; Lankin VZ
    Biull Eksp Biol Med; 1996 Dec; 122(12):651-4. PubMed ID: 9280465
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinicopathologic features of 234 cases with borderline ovarian tumors].
    Ren J; Lou JY; Liu H; Wang P; Zhang JW; Yang KX; Wang HJ; Qie MR; Peng ZL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):116-20. PubMed ID: 19570422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.